ArticleRevista da Associacao Medica Brasileira (1992)2026
Evaluation of prognostic biomarkers for exacerbation frequency in patients with chronic obstructive pulmonary disease.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic inflammation is closely associated with acute exacerbations of chronic obstructive pulmonary disease and may reflect the risk of future exacerbations. Blood-based inflammatory biomarkers represent simple and practical tools for identifying patients at increased risk. The aim of this study was to evaluate the association between systemic inflammatory biomarkers measured during stable chronic obstructive pulmonary disease and overall exacerbation burden across Global Initiative for Chronic Obstructive Lung Disease stages.
methodsThis retrospective cohort study included 132 patients with chronic obstructive pulmonary disease followed for at least 2 years. Clinical, functional, and laboratory data obtained during clinically stable periods were analyzed. Systemic inflammatory indices (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, aggregate index of systemic inflammation, and modified Glasgow prognostic score) were calculated. Exacerbation frequency was defined as the annualized number of moderate-to-severe exacerbations. Patients were classified according to Global Initiative for Chronic Obstructive Lung Disease groups A, B, and E, and associations between inflammatory biomarkers and clinical outcomes were evaluated using appropriate statistical methods, including receiver operating characteristic curve analyses.
resultsElevated levels of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, aggregate index of systemic inflammation, modified Glasgow prognostic score, and C-reactive protein were significantly associated with increased exacerbation frequency and hospitalization rates in the overall cohort (all p<0.05), whereas systemic inflammation response index showed no significant association. Receiver operating characteristic analyses demonstrated moderate discriminative ability of C-reactive protein and inflammatory indices for predicting frequent exacerbations.
conclusionSystemic inflammatory biomarkers were associated with adverse clinical outcomes in patients with chronic obstructive pulmonary disease and were significantly related to exacerbation frequency and severity. These findings suggest that systemic inflammatory markers may be useful for overall clinical assessment and identifying patients at increased risk of exacerbations, rather than for stage-specific risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.